AstraZeneca Gains 5.5% and Sees 2026 Estimate Raised to $10.30
AstraZeneca holds a #3 (Hold) rating with a VGM Score of B and a top-tier Momentum Score A after shares rose 5.5% over the past four weeks. Three analysts lifted fiscal 2026 earnings estimates by $0.01 to $10.30 per share, reflecting a +3.6% average earnings surprise.
1. Rating and Style Scores
AstraZeneca holds a #3 (Hold) rating with a VGM Score of B and a Momentum Style Score of A, indicating strong trend-based performance.
2. Recent Price Performance
Shares have climbed 5.5% over the last four weeks, underlining momentum-driven investor interest.
3. Analyst Estimate Revisions
Three analysts raised fiscal 2026 earnings estimates by $0.01 to $10.30 per share, contributing to an average +3.6% earnings surprise.
4. Business Segment Overview
The company’s portfolio includes cardiovascular, renal and metabolism; respiratory and immunology; oncology; rare diseases; vaccines; and other operations.